Related Articles
Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients
SOCS1 silencing can break high-dose dendritic cell immunotherapy-induced immune tolerance
A novel potential effective strategy for enhancing the antitumor immune response in breast cancer patients using a viable cancer cell‑dendritic cell‑based vaccine
Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti‑tumor immunity by promoting the secretion of IFN‑γ and IL‑2 from T cells
Silencing of suppressor of cytokine signaling 1 enhances the immunological effect of mucin 1-calreticulin-primed 4T1 cell-treated dendritic cells in breast cancer treatment